



Dawkins, N., Yates, T., Soczawa-Stronczyk, A., Bocian, M., Edwardson, C., Maylor, B., Davies, M., Khunti, K., & Rowlands, A. (2022). Normative wrist-worn accelerometer values for self-paced walking and running: a walk in the park. *Journal of Sports Sciences*. <https://doi.org/10.1080/02640414.2021.1976491>

**Document version**

Peer reviewed version

**Licence**

CC BY-NC

**Copyright information**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above.

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

**Takedown policy**

Any individual, whether within or external to the University, has the right to request the removal of content from the Leeds Trinity University Repository, on the grounds that it breaches copyright, is in any other way unlawful, or represents research misconduct.

Complaints can be submitted via the Repository Complaints Form at <https://www.leedstrinity.ac.uk/media/site-assets/documents/key-documents/pdfs/repository-complaints-form.pdf>

1 **Normative wrist-worn accelerometer values for self-paced walking and**  
2 **running: A Walk in the Park**

3 Wrist accelerometer norms for self-paced walking

4 Nathan P. Dawkins<sup>1,2</sup> (ORCID: 0000-0002-6374-7908), Tom Yates<sup>1,2</sup> (ORCID: 0000-0002-  
5 5724-5178), Artur A. Soczawa-Stronczyk<sup>5</sup> (ORCID: 0000-0002-3393-8404), Mateusz Bocian<sup>5,6,7</sup>  
6 (ORCID: 0000-0002-3539-5474), Charlotte L. Edwardson<sup>1,2</sup> (ORCID: 0000-0001-6485-9330),  
7 Ben Maylor<sup>1,2</sup> (ORCID: 0000-0002-4503-0479), Melanie J. Davies<sup>1,2</sup> (ORCID: 0000-0002-9987-  
8 9371), Kamlesh Khunti<sup>1,4</sup> (ORCID: 0000-0003-2343-7099), Alex V. Rowlands<sup>1,2,3</sup> (ORCID:  
9 0000-0002-1463-697X).

- 10 1. Diabetes Research Centre, University of Leicester, Leicester General Hospital,  
11 Leicester, UK  
12 2. NIHR Leicester Biomedical Research Centre, UK  
13 3. Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute  
14 for Health Research, Division of Health Sciences, University of South Australia,  
15 Adelaide, Australia  
16 4. NIHR Applied Research Collaboration East Midlands, Leicester General Hospital,  
17 UK  
18 5. School of Engineering, University of Leicester, Leicester, UK  
19 6. Biomechanics and Immersive Technology Laboratory, University of Leicester,  
20 Leicester, UK  
21 7. Department of Bridges and Railways, Wrocław University of Science and  
22 Technology, Poland

24  
25  
26 Nathan Dawkins, Diabetes Research Centre, University of Leicester, Leicester General Hospital,  
27 Leicester, LE5 4PW, UK. Nd177@le.ac.uk. Tel: +44 116 258 4322

28 Word count: 3,848

29

30

31

32

33 **Abstract**

34 This study aimed to a) determine whether wrist acceleration varies by accelerometer brand, wear  
35 location, and age for self-paced ‘slow’, ‘normal’ and ‘brisk’ walking; b) develop estimates of  
36 normative acceleration values for self-paced walking and running for adults. One-hundred-and-  
37 three adults (40-79 years) completed self-paced ‘slow’, ‘normal’ and ‘brisk’ walks, while wearing  
38 three accelerometers (GENEActiv, Axivity, ActiGraph) on each wrist. A sub-sample (n=22)  
39 completed a self-paced run. Generalized estimating equations were used to establish differences  
40 by accelerometer brand, wrist, and age-group (walking only, 40-49, 50-59, 60-69, 70-79 years) for  
41 self-paced walking and running. Brand\*wrist interactions showed ActiGraph dominant wrist  
42 values were ~10% lower than GENEActiv/Axivity values for walking and running, and non-  
43 dominant ActiGraph values were ~5% lower for running only (p<0.001). Acceleration during  
44 brisk walking was lower in those aged 70-79 (p<0.05). Estimates of normative acceleration values  
45 (non-dominant wrist, all brands; dominant wrist GENEActiv/Axivity) for slow and normal  
46 walking were 140 mg and 210 mg, respectively. For brisk walking, values were 350 mg in those  
47 aged 40-69 years, but 270 mg in those aged 70-79 years. Accelerations >600 mg approximated  
48 running. These values facilitate interpretation of accelerometer-determined physical activity in  
49 user-friendly terms appropriate for large cohort and epidemiological datasets.

50 Keywords: PHYSICAL ACTIVITY, DEVICE MEASURED, ACCELEROMETER, ACTIVITY  
51 MONITORS

52

53

54

55

56

57

58

59

60 **Abbreviations**

61 Body mass index - BMI

62 Euclidean norm minus 1  $g$  – ENMO

63 Generalised estimating equation - GEE

64 Metabolic equivalent of task - MET

65 Milli-gravitational unit – mg

66 Moderate-to-vigorous physical activity – MVPA

67

68

69

70

Author Accepted Copy

## 71 **Introduction**

72 When wearable accelerometers are used to assess physical activity, a cut-point approach is  
73 frequently used to translate the data into clinically meaningful outcomes, e.g., time spent in  
74 moderate-to-vigorous physical activity (MVPA) or brisk walking. However, there are multiple cut-  
75 points available in the literature, meaning that data are often not comparable between studies. For  
76 example, estimates of the percentage of adults meeting the MVPA guidelines can vary from 5 to  
77 98%, depending on which cut-points are used (Loprinzi et al., 2012). Similar variation exists when  
78 comparisons are made for children with the percentage meeting the guidelines varying from 8-  
79 98% (Migueles et al., 2019a).

80 Cut-point values frequently used to classify adults' MVPA from raw accelerometer data (milli-  
81 gravitational units (mg)) typically come from relatively small laboratory studies (Hildebrand et al.,  
82 2014, Esliger et al., 2011, Duncan et al., 2020, Fraysse et al., 2020). A recent paper applied the  
83 widely used 100 mg MVPA cut-point (Hildebrand et al., 2014) for wrist worn accelerometers, to  
84 describe accelerometer-determined physical activity levels in people with chronic disease in the  
85 UK Biobank prospective cohort study (Barker et al., 2019a), the most extensive study to date to  
86 incorporate device-based measures of physical activity (Doherty et al., 2017). In a commentary on  
87 the paper, Dibben and colleagues (2019) suggested that in people with chronic disease, e.g., heart  
88 failure, the MVPA acceleration cut-point should be closer to 50 mg, reflecting this population's  
89 reduced exercise capacity. They subsequently applied this lower cut-point to data from participants  
90 with heart failure (Dibben et al., 2020). Using population specific cut-point values has been  
91 suggested previously, e.g., in relation to age-group and/or obesity status, wherein lower  
92 acceleration values for a given activity intensity were seen for slightly older obese individuals  
93 compared with younger healthy individuals (Aadland and Anderssen, 2012). Whilst

94 acknowledging the point, the response to the commentary highlighted that this would not be  
95 possible until population-specific values for accelerometer data were available (Barker et al.,  
96 2019b).

97 Accelerometer data can also be translated in terms of indicative activities, e.g., time spent walking.  
98 As little as 10 minutes per day of device-measured brisk walking has been shown to reduce the  
99 risk of premature mortality (Chudasama et al., 2019). Self-reported brisk walking has also been  
100 associated with improved all-cause and cardiovascular mortality outcomes in middle-aged and  
101 older people (Yates et al., 2017, Stamatakis et al., 2018). Walking is an activity which is familiar  
102 to many people and easy to interpret at a population level. However, as people get older, the  
103 walking speed they perceive as 'brisk' tends to decrease, reflecting lower physical fitness and  
104 reduced exercise capacity (Himann et al., 1988, Bohannon and Andrews, 2011). This is reflected  
105 in the preferred walking speed being lower in adults who are older (Karavirta et al., 2020). Thus,  
106 establishing acceleration values associated with self-paced walking and running across different  
107 age groups would enable simple, but age-appropriate, translation of accelerometer-determined  
108 outcomes in large epidemiological datasets such as the UK Biobank.

109 In addition to the potential influence of age, device brand and wear location also affect the  
110 acceleration generated when walking and running (Rowlands et al., 2019b). Three research-grade  
111 accelerometer device brands recently used in sizeable physical activity studies are the GENEActiv,  
112 Axivity and ActiGraph (Doherty et al., 2017, Troiano, 2005, Brady et al., 2019), with the Axivity  
113 device used to collect accelerometer data in UK Biobank. When processed identically, physical  
114 activity outcomes from the GENEActiv device have previously been shown to be comparable to  
115 the Axivity device (Rowlands et al., 2018); however, the ActiGraph device appears to generate a  
116 lower acceleration value, particularly on the dominant wrist (Rowlands et al., 2019b). The UK

117 Biobank uses the Axivity at the dominant wrist, and the National Health and Nutrition Examination  
118 Survey (NHANES) uses the ActiGraph at the non-dominant wrist (Doherty et al., 2017, Troiano,  
119 2005). Current evidence is inconsistent on whether there is a disparity between accelerometer  
120 outcomes measured at the dominant and non-dominant wrist (Duncan et al., 2020). Thus, it is  
121 important to consider the potential influence of age, device brand and wear location when  
122 generating normative values.

123 Previous research assessing the association between accelerometer output and ambulatory speed  
124 is largely based on laboratory-based protocols, metronomes to control the walking pace, and/or  
125 employed treadmills (Hildebrand et al., 2014, Esliger et al., 2011, Duncan et al., 2020, Fraysse et  
126 al., 2020). Using a treadmill is effective for standardising walking and running speed. However,  
127 the energy cost can be higher than during overground walking (Barnett et al., 2015, Parvataneni et  
128 al., 2009) and the co-ordination between upper and lower arm limbs may also differ (Carpinella et  
129 al., 2010). Gait speed assessed in a laboratory can also differ from that assessed in daily life (Van  
130 Ancum et al., 2018). Thus, data from self-paced outdoor walking would provide a dataset with  
131 greater ecological validity and generalisability (Tudor-Locke and Rowe, 2012).

132 The main aim of this study was to facilitate simple and meaningful translation of wrist worn  
133 accelerometer data. To do this, we aimed to a) determine whether wrist acceleration varies by age-  
134 group, accelerometer brand and wear location during self-paced 'slow', 'normal' and 'brisk'  
135 walking and self-paced running, and b) develop estimates of normative acceleration values for  
136 self-paced walking and running for adults aged 40-79 years for commonly used accelerometers  
137 when placed on the dominant or non-dominant wrist.

## 138 **Methods**

### 139 **Participants and procedures**

140 A convenience sample of 105 adults (40 - 79 years of age) was recruited via email, social media,  
141 and direct contact. Ethical approval was obtained from the University of Leicester's College of  
142 Life Sciences ethics representatives in February 2019. Following informed consent,  
143 anthropometric measures were taken (height, mass, and body mass index (BMI)). Demographic  
144 variables (age, sex and ethnicity) were self-reported. Ethnicity was categorised as white European  
145 or other due to small numbers in the other categories of ethnicity. Age was categorised into four  
146 age groups: 40-49, 50-59, 60-69 and 70-79 years. Participants were fitted with three  
147 accelerometers on each wrist: ActiGraph Link, Axivity AX3 and GENEActiv. These devices have  
148 high inter-device reliability (Ladha et al., 2013, Esliger et al., 2011).

149 Participants completed three self-paced walks (slow, normal and brisk) in a park along a hard path.  
150 Each participant completed the study visits individually. The walks were undertaken in order of  
151 ascending speed. For the slow walk, participants were asked to walk "at a pace they may use when  
152 strolling along chatting", for the normal walk, to "walk at their preferred pace", and for the brisk  
153 walk, to "walk at a pace that feels brisk or purposeful". Next, participants were given the option  
154 of a self-paced run around the park. For the run, participants were asked to "maintain a comfortable  
155 and consistent pace which they could maintain for 5 km". The start and end time of each walk and  
156 run was recorded and used to calculate walking speed.

### 157 **Accelerometer setup and data processing**

158 The accelerometers used were the Axivity AX3 (Axivity Ltd, Newcastle, UK), GENEActiv  
159 Original (Activinsights Ltd., Cambridgeshire, UK) and ActiGraph GT9X Link (ActiGraph LLC,  
160 Pensacola, FL, USA). The ActiGraph, Axivity and GENEActiv were worn on both wrists i.e., the



161 participants wore six accelerometers in total. The first device was placed at the wrist, with a second  
162 proximal to this and a third attached on top of one of the first two devices, with the order of devices  
163 consistent between wrists for each participant. The relative position of each device was randomly  
164 generated for each participant. All accelerometers were synchronised to the computer clock to  
165 ensure consistency in identification of walk and run times. The monitors were initialised to collect  
166 data at 100 Hz with a dynamic range of +/- 8 g, where g is equal to the Earth's gravitational  
167 acceleration. The Axivity devices were set up, data downloaded and saved in .cwa format with  
168 OmGui open-source software (OmGui Version 1.0.0.37, Open Movement, Newcastle, UK). The  
169 GENEActiv monitors were initialised, data downloaded and saved as .bin files using GENEActiv  
170 PC software version 3.2. The ActiGraph monitors were initialised, data downloaded and saved in  
171 raw format as .gt3x, then converted to .csv format for further processing, using ActiLife version  
172 6.13.4.

173 All accelerometer data were processed using GGIR package in R version 1.10-7 ([https://cran.r-](https://cran.r-project.org/web/packages/GGIR/)  
174 [project.org/web/packages/GGIR/](https://cran.r-project.org/web/packages/GGIR/)) (Migueles et al., 2019b). The default GGIR settings were used  
175 to process the data and Euclidean Norm minus 1 g (ENMO, the vector magnitude taken from the  
176 three axes minus the value of gravity (g)  $(x^2 + y^2 + z^2)^{1/2} - 1$ , with negative values rounded up to  
177 zero (Hildebrand et al., 2014)) was the accelerometer signal aggregation metric used. Signal  
178 processing in GGIR includes auto-calibration using local gravity as a reference (van Hees et al.,  
179 2014), detection of sustained abnormally high values, calculation of the average magnitude of  
180 dynamic acceleration (i.e., the vector magnitude of acceleration corrected for gravity (ENMO) in  
181 milli-gravitational units (mg) averaged over 5 second epochs (van Hees et al., 2014). Files were  
182 excluded if accelerometer files showed post-calibration error greater than 0.01 g (10 mg)  
183 (Rowlands et al., 2016).

184 Epoch level comma-separated values files (.csv) were generated and matched across monitors for  
185 each participant. The time period and accelerations associated with each walk/run were identified,  
186 and the mean acceleration for each walk/run was calculated. Each walk/run was trimmed by 20  
187 seconds at the start and the end in order to account for acceleration and deceleration at the start  
188 and end of each walk/run. Average acceleration for each walk and run was reported in milli-  
189 gravitational units (mg).

## 190 **Statistical analysis**

191 Descriptive data were calculated for each variable using the mean (SD). Data were split by age  
192 group for the walking sample but presented for the whole group for running due to the low number  
193 of participants opting to undertake the run.

### 194 *Acceleration during self-paced slow, normal and brisk walking*

195 General estimating equation (GEE) models with an exchangeable correlation matrix, taking  
196 account of repeated measures was used to explore whether the acceleration (mg, dependent  
197 variable) at each walking pace (slow, normal, brisk) differed by accelerometer brand, and/or age  
198 group. As previous research suggests that brand differences may differ by placement (Hildebrand  
199 et al., 2014; Rowlands et al., 2019b), first we assessed whether associations between acceleration  
200 and pace for a given wrist (dominant/non-dominant) were moderated by device brand, using a  
201 'wear location \* device brand' interaction term. There was a main effect for wear location ( $p =$   
202 0.002) and an interaction between wear location (dominant/non-dominant) and device brand ( $p <$   
203 0.001) (supplementary Table S1). The interaction showed that on the dominant wrist the ActiGraph  
204 produced a lower acceleration than either the GENEActiv or Axivity, while there was no  
205 significant difference on the non-dominant wrist. Hence, analyses were stratified by wear location  
206 (dominant and non-dominant wrist). Potential covariates included in the model were sex, height,

207 and mass. The interaction between walking pace and age group was explored to determine whether  
208 normative values should differ by age group.

### 209 *Acceleration during self-paced running*

210 Similarly, GEE models were used to explore whether the acceleration (mg, dependent variable)  
211 during self-paced running differed by accelerometer brand. We assessed whether the acceleration  
212 during running for each wrist was moderated by device brand, using a ‘wear location \* device  
213 brand’ interaction term. There was a significant interaction between wear location (dominant/non-  
214 dominant) and device brand ( $p < 0.001$ ) (supplementary Table S2). The interaction showed that  
215 on both wrists the ActiGraph produced a lower acceleration than either the GENEActiv or Axivity,  
216 however the difference was less on the non-dominant wrist than on the dominant wrist. Hence,  
217 analyses were stratified by wear location (dominant and non-dominant wrist). As the sample size  
218 was insufficient to break down into age-groups, age (years) was instead entered as a co-variate  
219 with sex, height, and mass.

220 All analyses were run using Stata 16 (StataCorp LP, Texas, USA).

## 221 **Results**

222 Descriptive information for the sample, including speed and acceleration for self-paced walking  
223 (by age-group) and self-paced running, can be seen in Table 1. Of the 105 participants consented  
224 into the study, two participants were excluded (one unable to complete the study visit in full and  
225 one removed due to device error). Therefore, 103 participants were included in the analysis. The  
226 running sample was a self-selected sub-sample of the walking dataset; 25 participants volunteered  
227 to complete the running protocol, and three were excluded (due to device error) resulting in 22  
228 participants data for the analysis (Table 1).

229 **Acceleration during self-paced slow, normal and brisk walking**

230 *Self-paced walking*

231 *Dominant wrist*

232 Mean (SD) acceleration for the slow, normal and brisk walk across the devices at the dominant  
233 wrist was 132.9 mg (46.3 mg), 202 mg (67.7 mg) and 323.9 mg (160.1 mg) respectively (values  
234 not shown in table). Adjusted means for the normal and brisk walks were 69.1 mg (95% CI: 61.6,  
235 76.6 mg) and 191 mg (164.9, 217.2 mg) higher, respectively than the slow walk (both  $p < 0.001$ )  
236 (Table 2). The GENEActiv and Axivity devices were not significantly different; however, the  
237 mean acceleration measured by the ActiGraph device was 18.6 mg (26.0, 11.2 mg) lower ( $p <$   
238  $0.001$ ) (Table 2).

239 The association between age group and acceleration was modified by walking pace category ( $p =$   
240  $0.026$ ), such that there was a significant difference in acceleration between age groups for brisk  
241 walking but not at slow or normal walking (Figure 1a). For those aged 70-79 years, the acceleration  
242 for brisk walking was on average 89.7 mg (95% CI: 81.4, 97.9 mg, Figure 1a) lower than those in  
243 the reference group (40-49 years).

244 *Non-dominant wrist*

245 Mean (SD) acceleration for the slow, normal and brisk walk across the devices at the non-dominant  
246 wrist was 145 mg (56 mg), 218.2 mg (82.1 mg) and 333.9 mg (179.3 mg) respectively (values not  
247 shown in table). Adjusted means for the normal and brisk walks were 73.2 mg (95% CI: 65.3, 81.2  
248 mg) and 194.9 mg (167.4, 222.5 mg) higher, respectively than the slow walk (both  $p < 0.001$ )  
249 (Table 2). In contrast to the dominant wrist, no significant difference was seen between the device  
250 brands.

251 Consistent with the dominant wrist, the association between age group and acceleration was  
252 modified by walking pace category, ( $p=0.005$ ), with a significant difference in acceleration  
253 between age groups for brisk walking but not slow or normal walking (Figure 1b). In 70-79 year  
254 olds, the acceleration for brisk walking was on average 110.7 mg (95% CI: 95.1, 126.4 mg) lower  
255 than those in the reference group (40-49 years).

### 256 *Self-paced running*

257 Mean (SD) acceleration for self-paced running across the devices was 900.2 mg (225.8 mg) at the  
258 dominant wrist and 859.9 mg (192.5 mg) at the non-dominant wrist (values not shown in table).  
259 Consistent with walking, the GENEActiv and Axivity devices were not significantly different at  
260 either wrist. However, the mean acceleration measured by the ActiGraph device was 89.2 mg  
261 (121.1, 57.3 mg) lower ( $p < 0.001$ ) at the dominant wrist and 28.8 mg (48.1, 9.5 mg) lower ( $p =$   
262 0.003) at the non-dominant wrist (Table 3).

### 263 *Normative acceleration values for self-paced walking and running*

264 Consistent normative acceleration values for interpreting/translating accelerometer data in terms  
265 of self-paced slow and normal walking are appropriate for those aged 40-79 years. However, based  
266 on the findings from the interaction model, for brisk walking it is appropriate to present the  
267 normative values based on age: those aged up to 69 years and those aged 70 years and over.  
268 Regarding device brand and wear location, there were no significant differences for self-paced  
269 walking, with the exception of the ActiGraph worn at the dominant wrist which was approximately  
270 10% lower (Table 2, Figure 1a). Thus, to facilitate simple translation of accelerometer data, we  
271 present estimates of normative acceleration appropriate for all three accelerometer brands worn on  
272 the non-dominant wrist, and the GENEActiv or Axivity worn on the dominant wrist. For slow and

273 normal walking normative values are for appropriate for all age groups (40-79 years). For brisk  
274 walking, normative values are presented for those aged up to 69 years and those over 70 years old.  
275 Acceleration values of 140 mg and 210 mg approximated slow and normal walking, respectively.  
276 For those aged up to 69 years and 70 years and over, an acceleration value of 350 mg and 270 mg  
277 respectively approximated brisk walking. However, if applied to ActiGraph data from the  
278 dominant wrist, these values should be decreased by 10%.

279 For estimating a similar value for self-paced running, it was not possible to differentiate into age-  
280 groups due to sample size. For the 95% of the participants who ran at  $>8 \text{ km}\cdot\text{h}^{-1}$ , acceleration was  
281  $>600 \text{ mg}$  for all devices (Figure 2), despite the significantly lower acceleration values for the  
282 ActiGraph. Thus, a value of  $>600 \text{ mg}$  is recommended to represent self-paced running.

## 283 **Discussion**

284 This study presents the accelerations recorded by wrist-worn accelerometers when undertaking  
285 self-paced slow, normal and brisk walking. Linking accelerations to self-paced walking facilitates  
286 use of accelerometer data to estimate the prevalence of physical activity of sufficient relative  
287 intensity to potentially benefit health (Chudasama et al., 2019, Rowlands et al., 2019a).  
288 Accelerations measured at the wrist clearly differentiated between self-paced slow, normal and  
289 brisk walking, irrespective of age-group, device or wrist of wear. The lower accelerations  
290 associated with self-paced brisk walking in the older age groups reflected their lower absolute  
291 speed, evident here and consistent with previous research (Bohannon and Andrews, 2011). People  
292 aged 70-79 years walked  $0.7 \text{ km}\cdot\text{h}^{-1}$  slower and measured acceleration was correspondingly 100  
293 mg lower than those aged 40-49 years when walking briskly. This difference could lead to  
294 underestimation of self-paced brisk walking when translating accelerometer assessed physical  
295 activity in older age groups. Thus, while the normative acceleration values for slow and normal

296 walking are consistent across age groups, for brisk walking the estimate is lower for those aged  
297 70-79 years.

298 The approximations hold across all devices on the non-dominant wrist. Researchers using the  
299 ActiGraph on the dominant wrist should be aware that values were approximately 10% lower than  
300 the other devices, consistent with previous research (Rowlands et al., 2019b), and the normative  
301 values should be adjusted accordingly. However, a value of  $\geq 600$  mg was reflective of running in  
302 our self-selected sub-sample irrespective of device.

303 MVPA cut-points are typically based on 3 METs (metabolic equivalent of task), which equates to  
304 walking at  $4 \text{ km}\cdot\text{h}^{-1}$  (Ainsworth et al., 2011). An acceleration value of 100 mg has been presented  
305 to quantify MVPA ( $>3$  METs) from wrist accelerometry during laboratory-based treadmill  
306 walking in adults (Hildebrand et al., 2014). However, in this study the self-paced walking speeds  
307 associated with slow ( $4.6 \text{ km}\cdot\text{h}^{-1}$ ), normal ( $5.6 \text{ km}\cdot\text{h}^{-1}$ ) and brisk walking ( $6.5 \text{ km}\cdot\text{h}^{-1}$ ) were all  
308 higher than  $4 \text{ km}\cdot\text{h}^{-1}$ , with corresponding acceleration values on average above 100 mg. Thus,  
309 these findings indicate that self-paced walking, even at a pace perceived as slow, people exceeded  
310 the 100 mg threshold. This indicates a potential discrepancy between metabolic and behavioural  
311 definitions of moderate intensity walking. For example, MVPA can be exemplified as ‘brisk  
312 walking’ (Kwan et al., 2020, Bjørkelund et al., 2016), but note the 3 MET lower bound of the  
313 MVPA category aligns with the energy expenditure associated with walking at  $4 \text{ km}\cdot\text{h}^{-1}$   
314 (Ainsworth et al., 2011), which was  $\sim 1$  standard deviation slower than the mean speed of a self-  
315 paced slow walk in the current study.

316 Walking is an easily understandable form of physical activity. Thus, to illustrate the association  
317 between accelerometer-determined physical activity and premature mortality in the UK Biobank  
318 cohort, Chudasama and colleagues used a value of 250 mg to translate accelerometer data in terms

319 of time spent walking briskly (Chudasama et al., 2019). The 250 mg acceleration threshold was  
320 estimated from the linear regression equation presented by Hildebrand and colleagues (2014) using  
321 4.3 METs, the energy expenditure indicative of walking at a 'brisk pace for exercise' (Ainsworth  
322 et al., 2011). This demonstrates how thresholds can be used to develop simple, but effective, public  
323 health messages from associations between accelerometer-determined physical activity and health.  
324 In the current study, 250 mg equates to a pace between a self-paced normal and brisk walk for 40-  
325 69 year olds, but for those aged 70-79 years it approximated a self-paced brisk walk. Thus, for  
326 those 40-69 years, prescribing self-paced brisk walking may elicit a higher intensity than intended.  
327 Clinicians should bear this in mind when recommending or prescribing brisk walking.

328 Acceleration data from the ActiGraph were around 10% lower at the dominant wrist during  
329 walking and running and 5% lower for the non-dominant wrist when running. This has been shown  
330 previously, predominantly for acceleration measured at the dominant wrist (Rowlands et al., 2018).  
331 The relatively lower output from the ActiGraph may be related to filtering applied by the  
332 ActiGraph proprietary software to the data (Rowlands et al., 2019b). As accelerations are higher  
333 at the dominant wrist, this explains why it may be evident for the dominant wrist only during  
334 walking, but noticeable at both wrists for the higher intensity activity or running.

335 Strengths of the study include use of three of the main research-grade accelerometers, and self-  
336 paced walking and running in a free-living environment, which more accurately represents daily  
337 life gait and walking (Van Ancum et al., 2018, Barnett et al., 2015). However, there are several  
338 limitations that should be noted. Firstly, despite having a larger total sample than previous studies,  
339 this study is limited by the relatively small numbers in the oldest age-group and was pre-  
340 dominantly white Europeans. Secondly, as three different brands of devices were used, only one  
341 could be placed directly on the optimal wrist position. However, the relative placement of the



342 monitors was randomised, as in previous studies (Rowlands et al., 2019b, Plekhanova et al., 2020).  
343 Thirdly, participants are likely to be healthier than the general population which could lead to  
344 faster walking speeds for a given pace compared to those recently presented in a large meta-  
345 analysis (Bohannon and Andrews, 2011, Murtagh et al., 2020). For example, recent research has  
346 shown that approximately  $4.4 \text{ km}\cdot\text{h}^{-1}$  was the preferred walking speed of someone aged 70 years,  
347 whereas in this study  $4.4 \text{ km}\cdot\text{h}^{-1}$  equated more closely to their slow self-paced walk (Karavirta et  
348 al., 2020). However, the normal walking speeds for the 40-69 years group are similar to others  
349 reported in the literature (Taylor et al., 2010). Finally, the methods used in this study for the  
350 translation of accelerometer data into time spent walking assumes that accelerations above the  
351 thresholds comes from ambulation. This may be a reasonable assumption given that walking is a  
352 major contributor to physical activity, particularly activity in older adults (Valenti et al., 2016).

353 In conclusion, these estimates of normative accelerations for self-paced walking and running  
354 facilitate simple but meaningful public-health friendly translation of accelerometer data (Dawkins  
355 et al., 2020, Rowlands et al., 2019a), that is relevant to different age groups, and can be easily  
356 applied to large datasets. Application of the acceleration values presented herein will facilitate age-  
357 specific and user-friendly translation of accelerometer-determined physical activity. These values  
358 may be particularly useful for large cohort or epidemiological datasets.

359 Future research should build on the normative values presented to expand the generalisability of  
360 values and, where necessary, facilitate the generation of values specific to a broader range of  
361 populations. Further to age, ethnic differences in walking speed could be explored, as South Asian  
362 populations are often shorter and lighter than White Europeans (Ntuk et al., 2017), potentially  
363 affecting the relationship between speed and acceleration.

364 **Acknowledgments**

365 The authors would like to thank Megan Chiffers for her assistance with data collection and the  
366 participants for their involvement with this study. University of Leicester authors are supported by  
367 the NIHR Leicester Biomedical Research Centre, and the NIHR Applied Research Collaboration  
368 (ARC) East Midlands. The views expressed are those of the authors and not necessarily those of  
369 the NHS, NIHR, or Department of Health.

370 Author Contributions: NPD, AVR, TY, AASS and MB planned the study. NPD and AASS  
371 undertook data collection. NPD completed the main analysis of the study, with contributions from  
372 AVR and TY. NPD prepared the first draft of the manuscript. All authors read, provided feedback  
373 and approved the final manuscript.

374 **Disclosure of interest:**

375 The authors report no conflict of interest.

376 **Funding:**

377 No funding was received to conduct this research.

378 **References**

- 379 AADLAND, E. & ANDERSSON, S. A. 2012. Treadmill calibration of the Actigraph GT1M in  
380 young-to-middle-aged obese-to-severely obese subjects. *Journal of obesity*, 2012.
- 381 AINSWORTH, B. E., HASKELL, W. L., HERRMANN, S. D., MECKES, N., BASSETT JR, D.  
382 R., TUDOR-LOCKE, C., GREER, J. L., VEZINA, J., WHITT-GLOVER, M. C. & LEON,  
383 A. S. 2011. 2011 Compendium of Physical Activities: a second update of codes and MET  
384 values. *Medicine & science in sports & exercise*, 43, 1575-1581.
- 385 BARKER, J., SMITH BYRNE, K., DOHERTY, A., FOSTER, C., RAHIMI, K.,  
386 RAMAKRISHNAN, R., WOODWARD, M. & DWYER, T. 2019a. Physical activity of  
387 UK adults with chronic disease: cross-sectional analysis of accelerometer-measured  
388 physical activity in 96 706 UK Biobank participants. *International Journal of*  
389 *Epidemiology*, 48, 1167-1174.
- 390 BARKER, J., SMITH BYRNE, K., DOHERTY, A., FOSTER, C., RAHIMI, K.,  
391 RAMAKRISHNAN, R., WOODWARD, M. & DWYER, T. 2019b. Response to: One size  
392 does not fit all—application of accelerometer thresholds in chronic disease. *International*  
393 *Journal of Epidemiology*.
- 394 BARNETT, A., CERIN, E., VANDELANOTTE, C., MATSUMOTO, A. & JENKINS, D. 2015.  
395 Validity of treadmill-and track-based individual calibration methods for estimating free-  
396 living walking speed and VO<sub>2</sub> using the Actigraph accelerometer. *BMC Sports Science,*  
397 *Medicine and Rehabilitation*, 7, 1-11.

398 BJØRKELUND, O. A., DEGERUD, H. & BERE, E. 2016. Socio-demographic, personal,  
399 environmental and behavioral correlates of different modes of transportation to work  
400 among Norwegian parents. *Archives of public health*, 74, 1-9.

401 BOHANNON, R. W. & ANDREWS, A. W. 2011. Normal walking speed: a descriptive meta-  
402 analysis. *Physiotherapy*, 97, 182-189.

403 BRADY, E. M., HALL, A. P., BALDRY, E., CHATTERJEE, S., DANIELS, L. J.,  
404 EDWARDSON, C., KHUNTI, K., PATEL, M. I., HENSON, J. J. & ROWLANDS, A.  
405 2019. Rationale and design of a cross-sectional study to investigate and describe the  
406 chronotype of patients with type 2 diabetes and the effect on glycaemic control: the  
407 CODEC study. *BMJ open*, 9.

408 CARPINELLA, I., CRENNNA, P., RABUFFETTI, M. & FERRARIN, M. 2010. Coordination  
409 between upper-and lower-limb movements is different during overground and treadmill  
410 walking. *European journal of applied physiology*, 108, 71-82.

411 CHUDASAMA, Y. V., KHUNTI, K. K., ZACCARDI, F., ROWLANDS, A. V., YATES, T.,  
412 GILLIES, C. L., DAVIES, M. J. & DHALWANI, N. N. 2019. Physical activity,  
413 multimorbidity, and life expectancy: a UK Biobank longitudinal study. *BMC medicine*, 17,  
414 108.

415 DAWKINS, N. P., YATES, T., EDWARDSON, C. L., MAYLOR, B., DAVIES, M. J.,  
416 DUNSTAN, D., HIGHTON, P. J., HERRING, L. Y., KHUNTI, K. & ROWLANDS, A.  
417 V. 2020. Comparing 24 h physical activity profiles: Office workers, women with a history  
418 of gestational diabetes and people with chronic disease condition(s). *Journal of Sports  
419 Sciences*, 1-8.

420 DIBBEN, G. O., GANDHI, M. M., TAYLOR, R. S., DALAL, H. M., METCALF, B., DOHERTY,  
421 P., TANG, L. H., KELSON, M. & HILLSDON, M. 2020. Physical activity assessment by  
422 accelerometry in people with heart failure. *BMC Sports Science, Medicine and  
423 Rehabilitation*, 12, 1-12.

424 DIBBEN, G. O., TAYLOR, R. S., DALAL, H. M. & HILLSDON, M. 2019. One size does not fit  
425 all—application of accelerometer thresholds in chronic disease. *International Journal of  
426 Epidemiology*.

427 DOHERTY, A. R., JACKSON, D., HAMMERLA, N., PLÖTZ, T., OLIVIER, P., GRANAT, M.  
428 H., WHITE, T., VAN HEES, V. T., TRENELL, M. I. & OWEN, C. G. 2017. Large scale  
429 population assessment of physical activity using wrist worn accelerometers: The UK  
430 Biobank Study. *PloS one*, 12, e0169649.

431 DUNCAN, M. J., ROWLANDS, A., LAWSON, C., LEDDINGTON WRIGHT, S., HILL, M.,  
432 MORRIS, M., EYRE, E. & TALLIS, J. 2020. Using accelerometry to classify physical  
433 activity intensity in older adults: What is the optimal wear-site? *European journal of sport  
434 science*, 20, 1131-1139.

435 ESLIGER, D. W., ROWLANDS, A. V., HURST, T. L., CATT, M., MURRAY, P. & ESTON, R.  
436 G. 2011. Validation of the GENE Accelerometer.

437 FRAYSSE, F., POST, D., ESTON, R., KASAI, D., ROWLANDS, A. V. & PARFITT, G. 2020.  
438 Physical activity intensity cut-points for wrist-worn GENEActiv in older adults. *Frontiers  
439 in Sports and Active Living*, 2.

440 HILDEBRAND, M., VT, V. A. N. H., HANSEN, B. H. & EKELUND, U. 2014. Age group  
441 comparability of raw accelerometer output from wrist- and hip-worn monitors. *Medicine  
442 & science in sports & exercise*, 46, 1816-24.

443 HIMANN, J. E., CUNNINGHAM, D. A., RECHNITZER, P. A. & PATERSON, D. H. 1988. Age-  
444 related changes in speed of walking. *Medicine & science in sports & exercise*, 20, 161-  
445 166.

446 KARAVIRTA, L., RANTALAINEN, T., SKANTZ, H., LISKI, I., PORTEGIJS, E. &  
447 RANTANEN, T. 2020. Individual scaling of accelerometry to preferred walking speed in  
448 the assessment of physical activity in older adults. *The Journals of Gerontology: Series A*,  
449 75 (9), e111-e118.

450 KWAN, R. Y., LEE, D., LEE, P. H., TSE, M., CHEUNG, D. S., THIAMWONG, L. & CHOI, K.-  
451 S. 2020. Effects of an mhealth brisk walking intervention on increasing physical activity  
452 in older people with cognitive frailty: pilot randomized controlled trial. *JMIR mHealth and*  
453 *uHealth*, 8, e16596.

454 LADHA, C., LADHA, K., JACKSON, D. & OLIVIER, P. Shaker table validation of  
455 OpenMovement AX3 accelerometer. Ahmerst (ICAMPAM 2013 AMHERST): In 3rd  
456 International Conference on Ambulatory Monitoring of Physical Activity and Movement,  
457 2013. 69-70.

458 LOPRINZI, P. D., LEE, H., CARDINAL, B. J., CRESPO, C. J., ANDERSEN, R. E. & SMIT, E.  
459 2012. The relationship of actigraph accelerometer cut-points for estimating physical  
460 activity with selected health outcomes: results from NHANES 2003-06. *Res Q Exerc Sport*,  
461 83, 422-30.

462 MIGUELES, J. H., CADENAS-SANCHEZ, C., TUDOR-LOCKE, C., LÖF, M., ESTEBAN-  
463 CORNEJO, I., MOLINA-GARCIA, P., MORA-GONZALEZ, J., RODRIGUEZ-  
464 AYLLON, M., GARCIA-MARMOL, E. & EKELUND, U. 2019a. Comparability of  
465 published cut-points for the assessment of physical activity: Implications for data  
466 harmonization. *Scandinavian Journal of Medicine & Science in Sport*, 29 (4), 223-574.

467 MIGUELES, J. H., ROWLANDS, A. V., HUBER, F., SABIA, S. & VAN HEES, V. T. 2019b.  
468 GGIR: A Research Community–Driven Open Source R Package for Generating Physical  
469 Activity and Sleep Outcomes From Multi-Day Raw Accelerometer Data. *Journal for the*  
470 *Measurement of Physical Behaviour*, 2, 188-196.

471 MURTAGH, E., MAIR, J. L., AGUAIR, E., TUDOR-LOCKE, C. & MURPHY, M. H. 2020.  
472 Outdoor walking speeds of apparently healthy adults: a systematic review and meta-  
473 analysis. *Sports Medicine*, 1-17.

474 NTUK, U., CELIS-MORALES, C., MACKAY, D., SATTAR, N., PELL, J. & GILL, J. 2017.  
475 Association between grip strength and diabetes prevalence in black, South-Asian, and  
476 white European ethnic groups: a cross-sectional analysis of 418 656 participants in the UK  
477 Biobank study. *Diabetic Medicine*, 34, 1120-1128.

478 PARVATANENI, K., PLOEG, L., OLNEY, S. J. & BROUWER, B. 2009. Kinematic, kinetic and  
479 metabolic parameters of treadmill versus overground walking in healthy older adults.  
480 *Clinical biomechanics*, 24, 95-100.

481 PLEKHANOVA, T., ROWLANDS, A. V., YATES, T., HALL, A., BRADY, E. M., DAVIES,  
482 M., KHUNTI, K. & EDWARDSON, C. L. 2020. Equivalency of sleep estimates:  
483 comparison of three research-grade accelerometers. *Journal for the Measurement of*  
484 *Physical Behaviour*, 1, 1-10.

485 ROWLANDS, A. V., DAWKINS, N. P., MAYLOR, B., EDWARDSON, C. L., FAIRCLOUGH,  
486 S. J., DAVIES, M. J., HARRINGTON, D. M., KHUNTI, K. & YATES, T. 2019a.  
487 Enhancing the value of accelerometer-assessed physical activity: meaningful visual

488 comparisons of data-driven translational accelerometer metrics. *Sports Medicine-Open*, 5,  
489 1-11.

490 ROWLANDS, A. V., MIRKES, E. M., YATES, T., CLEMES, S., DAVIES, M., KHUNTI, K. &  
491 EDWARDSON, C. L. 2018. Accelerometer-assessed physical activity in epidemiology:  
492 are monitors equivalent? *Medicine & Science in Sports & Exercise*, 50, 257-265.

493 ROWLANDS, A. V., PLEKHANOVA, T., YATES, T., MIRKES, E. M., DAVIES, M., KHUNTI,  
494 K. & EDWARDSON, C. L. 2019b. Providing a Basis for Harmonization of Accelerometer-  
495 Assessed Physical Activity Outcomes Across Epidemiological Datasets. *Journal for the*  
496 *Measurement of Physical Behaviour*, 2, 131-142.

497 ROWLANDS, A. V., YATES, T., DAVIES, M., KHUNTI, K. & EDWARDSON, C. L. 2016.  
498 Raw accelerometer data analysis with GGIR R-package: does accelerometer brand matter?  
499 *Medicine & Science in Sports & Exercise*. 48, 1935–1941.

500 STAMATAKIS, E., KELLY, P., STRAIN, T., MURTAGH, E. M., DING, D. & MURPHY, M.  
501 H. 2018. Self-rated walking pace and all-cause, cardiovascular disease and cancer  
502 mortality: individual participant pooled analysis of 50 225 walkers from 11 population  
503 British cohorts. *Br J Sports Med*, 52, 761-768.

504 TAYLOR, K. L., FITZSIMONS, C. & MUTRIE, N. 2010. Objective and subjective assessments  
505 of normal walking pace, in comparison with that recommended for moderate intensity  
506 physical activity. *International Journal of Exercise Science*, 3, 87.

507 TROIANO, R. P. 2005. A timely meeting: objective measurement of physical activity. *Medicine*  
508 *& science in sports & exercise*, 37, S487.

509 TUDOR-LOCKE, C. & ROWE, D. A. 2012. Using cadence to study free-living ambulatory  
510 behaviour. *Sports medicine*, 42, 381-398.

511 VALENTI, G., BONOMI, A. G. & WESTERTERP, K. R. 2016. Walking as a contributor to  
512 physical activity in healthy older adults: 2 week longitudinal study using accelerometry  
513 and the doubly labeled water method. *JMIR mHealth and uHealth*, 4, e56.

514 VAN ANCUM, J. M., VAN SCHOOTEN, K. S., JONKMAN, N. H., HUIJBEN, B., VAN  
515 LUMMEL, R. C., MESKERS, C. G., MAIER, A. B. & PIJNAPPELS, M. 2018. Gait speed  
516 assessed by a 4-meter walk test is not representative of daily-life gait speed in community-  
517 dwelling adults. *Maturitas*, 121, 28-34.

518 VAN HEES, V. T., FANG, Z., LANGFORD, J., ASSAH, F., MOHAMMAD, A., DA SILVA, I.  
519 C., TRENELL, M. I., WHITE, T., WAREHAM, N. J. & BRAGE, S. 2014. Autocalibration  
520 of accelerometer data for free-living physical activity assessment using local gravity and  
521 temperature: an evaluation on four continents. *J Appl Physiol (1985)*, 117, 738-44.

522 YATES, T., ZACCARDI, F., DHALWANI, N. N., DAVIES, M. J., BAKRANIA, K., CELIS-  
523 MORALES, C. A., GILL, J. M., FRANKS, P. W. & KHUNTI, K. 2017. Association of  
524 walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a  
525 UK Biobank observational study. *European heart journal*, 38, 3232-3240.

526

527

528

529

530 **Figure List**

531 **Figure 1.** Acceleration for each walking pace, by device brand and age group. Values are  
532 presented as marginal means with standard error bars: a) Dominant wrist b) Non-dominant wrist.  
533 \* Indicates significantly different from slow walk. G = GENEActiv, Ax = Axivity, AG =  
534 ActiGraph. Values are adjusted for sex, height and mass.

535  
536 **Figure 2.** Acceleration for self-selected running, by device brand and wear location. Values are  
537 presented as marginal means with standard error bars. \*Indicates ActiGraph was significantly  
538 lower than Axivity and GENEActiv. Values are adjusted for age, sex, height and mass.

539  
540

541

542

543

Author Accepted Copy

**Table 1.** Participant characteristics, walking speed and acceleration during self-paced slow, normal and brisk walking and running. Values mean (standard deviation) or N [%].

		Age-group				All Walking	Running
		40-49 y	50-59 y	60-69 y	70-79 y	(n = 103)	(n = 22)
		(n = 26)	(n = 25)	(n = 26)	(n = 26)		
	Age (years)	44.7 (3.2)	54.3 (2.6)	64.2 (2.7)	73.5 (2.7)	59.3 (11.1)	54 (9.8)
	Sex (Female)	17 [65.4]	15 [60]	16 [6.5]	11 [42.3]	59 [58.4]	10 [45.5]
	Ethnicity (WE)	23 [88.5]	19 [76]	22 [84.6]	26 [100]	93 [90.1]	20 [90.9]
	Height (cm)	169.9 (7.8)	165.6 (8.8)	168.3 (10.0)	170.5 (10.5)	168.5 (9.6)	170.9 (11.9)
	Mass (kg)	73.1 (11.7)	69.7 (16.4)	73.2 (12.9)	74.6 (12.0)	72.7 (13.6)	74.4 (13.1)
	Body mass index (BMI) (kg/m <sup>2</sup> )	25.4 (4.0)	25.2 (4.5)	25.8 (3.6)	25.7 (3.4)	25.6 (4)	25 (13.1)
<i>Physical activity variables</i>							
Self-paced slow walk	Speed (km·h <sup>-1</sup> )	4.7 (0.7)	4.6 (0.4)	4.6 (0.5)	4.5 (0.7)	4.6 (0.6)	-
	Acceleration (mg) *	150.5 (67.8)	146.8 (47.8)	134.7 (34.5)	124.1 (47.2)	138.9 (51.7)	-
Self-paced normal walk	Speed (km·h <sup>-1</sup> )	5.8 (0.6)	5.6 (0.6)	5.6 (0.6)	5.4 (0.6)	5.6 (0.6)	-
	Acceleration (mg) *	230.1 (83.1)	221.7 (78.6)	201.4 (48.2)	187.7 (80.8)	210.1 (75.7)	-
Self-paced brisk walk	Speed (km·h <sup>-1</sup> )	6.9 (0.6)	6.5 (0.7)	6.6 (0.4)	6.2 (0.6)	6.5 (0.6)	-
	Acceleration (mg) *	372.9 (170.1)	365.5 (210.8)	320.5 (133.7)	270.1 (136.9)	333.9 (170.0)	-
Self-paced running	Speed (km·h <sup>-1</sup> )	-	-	-	-	-	10.4 (1.8)
	Acceleration (mg) *	-	-	-	-	-	880.1 (210.0)

WE = White European

\*Average acceleration across all three device brands (GENEActiv, Axivity, ActiGraph) and wrist wear locations (dominant, non-dominant)

**Table 2.** Generalised estimating equation of acceleration for each walking pace (slow, normal, brisk) adjusted for clustering at participant level. Impact of device brand, age-group, sex, height, mass.

		Dominant wrist		Non-dominant wrist	
		Average acceleration (mg)		Average acceleration (mg)	
		Acceleration (mg)	95% CI	Acceleration (mg)	95% CI
<i>Categorical variables</i>					
Walking pace	Slow	0	Reference	0	Reference
	Normal	<b>69.1</b>	<b>61.6, 76.6</b>	<b>73.2</b>	<b>65.3, 81.2</b>
	Brisk	<b>191.0</b>	<b>164.9, 217.2</b>	<b>194.9</b>	<b>167.4, 222.5</b>
Sex	Female	0	Reference	0	Reference
	Male	-4.0	-49.0, 41.0	-26.3	-75.4, 22.8
Age-group	40-49 y	0	Reference	0	Reference
	50-59 y	-11.6	-60.9, 37.8	10.1	-62.8, 49.9
	60-69 y	-32.8	-71.3, 5.7	-37.3	-85.4, 10.4
	70-79 y	<b>-50.8</b>	<b>-93.7, -8.0</b>	<b>-58.4</b>	<b>-109.8, -7.0</b>
Device brand	GENEActiv	0	Reference	0	Reference
	Axivity	4.2	-0.5, 8.9	2.7	-5.1, 10.5
	ActiGraph	<b>-18.6</b>	<b>-26.0, -11.2</b>	1.5	-5.7, 8.8
<i>Continuous variables</i>					
Height (cm)		-2.3	-4.8, 0.1	-1.8	-5.0, 1.4
Mass (kg)		1.4	-0.16, 3.0	1.7	-0.3, 3.7
<i>Interaction term</i>					
Walking pace x age-group		<b>-11.1</b>	<b>-20.9, -1.4</b>	<b>-15.0</b>	<b>-25.5, -4.6</b>

Significant results denoted in bold ( $p < 0.05$ )

CI = confidence interval; y = years




**Table 3.** Generalised estimating equation of acceleration for running on each device brand (GENEActiv, Axivity, ActiGraph) adjusted for clustering at participant level. Impact of wear location age, sex, height, mass.

		Dominant wrist		Non-dominant wrist	
		Average acceleration (mg)		Average acceleration (mg)	
		Acceleration (mg)	95% CI	Acceleration (mg)	95% CI
<i>Categorical variables</i>					
Device brand	GENEActiv	0	Reference	0	Reference
	Axivity	-14.6	-51.1, 21.8	23.3	-17.0, 63.5
	ActiGraph	<b>-89.2</b>	<b>-121.1, -57.3</b>	<b>-28.8</b>	<b>-48.1, -9.5</b>
Sex	Female	0	Reference	0	Reference
	Male	17.5	-353.5, 388.6	-22.7	-317.2, 271.7
<i>Continuous variables</i>					
	Age (years)	0.9	-7.5, 9.2	-5.3	-12.7, 2.1
	Height (cm)	-7.8	-18.6, 3.1	-2.4	-11.7, 6.9
	Mass (kg)	0.6	-7.3, 8.4	2.9	-5.3, 11.0
<i>Marginal Means</i>					
	GENEActiv	934.8	836.1, 1,033.6	861.8	785.2, 938.3
	Axivity	920.2	836.1, 1,004.1	885.0	799.3, 970.7
	ActiGraph	<b>845.6</b>	<b>764.5, 926.8</b>	<b>833.0</b>	<b>767.5, 898.4</b>


Significant results denoted in bold (p <0.05)

CI = confidence interval; y = years


a)



b)



**Figure 1.** Acceleration for each walking pace, by device brand and age group. Values are presented as marginal means with standard error bars: a) Dominant wrist b) Non-dominant wrist. \* Indicates significantly different from slow walk. G = GENEActiv, Ax = Axivity, AG = ActiGraph. Values are adjusted for sex, height and mass.



**Figure 2.** Acceleration for self-selected running, by device brand and wear location. Values are presented as marginal means with standard error bars. \*Indicates ActiGraph was significantly lower than Axivity and GENEActiv. Values are adjusted for age, sex, height and mass.

Author Accepted Copy